[go: up one dir, main page]

WO2007042289A3 - Nanobodies™ and polypeptides against egfr and igf-ir - Google Patents

Nanobodies™ and polypeptides against egfr and igf-ir Download PDF

Info

Publication number
WO2007042289A3
WO2007042289A3 PCT/EP2006/009840 EP2006009840W WO2007042289A3 WO 2007042289 A3 WO2007042289 A3 WO 2007042289A3 EP 2006009840 W EP2006009840 W EP 2006009840W WO 2007042289 A3 WO2007042289 A3 WO 2007042289A3
Authority
WO
WIPO (PCT)
Prior art keywords
nanobodies
polypeptides
igf
nucleic acids
host cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2006/009840
Other languages
French (fr)
Other versions
WO2007042289A2 (en
Inventor
Toon Laeremans
Haard Hans De
Hendricus Renerus J Hoogenboom
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ablynx NV
Original Assignee
Ablynx NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ablynx NV filed Critical Ablynx NV
Priority to CA002624781A priority Critical patent/CA2624781A1/en
Priority to JP2008534933A priority patent/JP2009511032A/en
Priority to US12/083,406 priority patent/US20090252681A1/en
Priority to AU2006301426A priority patent/AU2006301426A1/en
Priority to EP06792421A priority patent/EP1934259A2/en
Publication of WO2007042289A2 publication Critical patent/WO2007042289A2/en
Publication of WO2007042289A3 publication Critical patent/WO2007042289A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The invention relates to polypeptides and Nanobodies against Epidermal Growth Factor Receptor (EGFR) and/or Insulin Growth Factor-I Receptor (IGF-IR). The invention also relates to nucleic acids encoding such Nanobodies and polypeptides; to methods for preparing such Nanobodies and polypeptides; to host cells expressing or capable of expressing such Nanobodies or polypeptides; to compositions, and in particular to pharmaceutical compositions, that comprise such Nanobodies, polypeptides, nucleic acids and/or host cells; and to uses of such Nanobodies, polypeptides, nucleic acids, host cells and/or compositions, in particular for prophylactic, therapeutic or diagnostic purposes.
PCT/EP2006/009840 2005-10-11 2006-10-11 Nanobodies™ and polypeptides against egfr and igf-ir Ceased WO2007042289A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002624781A CA2624781A1 (en) 2005-10-11 2006-10-11 Nanobodies tm and polypeptides against egfr and igf-ir
JP2008534933A JP2009511032A (en) 2005-10-11 2006-10-11 Nanobodies and polypeptides for EGFR and IGF-IR
US12/083,406 US20090252681A1 (en) 2005-10-11 2006-10-11 Nanobodies and Polypeptides Against EGFR and IGF-IR
AU2006301426A AU2006301426A1 (en) 2005-10-11 2006-10-11 NanobodiesTM and polypeptides against EGFR and IGF-IR
EP06792421A EP1934259A2 (en) 2005-10-11 2006-10-11 Nanobodies and polypeptides against egfr and igf-ir

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72593905P 2005-10-11 2005-10-11
US60/725,939 2005-10-11

Publications (2)

Publication Number Publication Date
WO2007042289A2 WO2007042289A2 (en) 2007-04-19
WO2007042289A3 true WO2007042289A3 (en) 2007-10-04

Family

ID=37837037

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/009840 Ceased WO2007042289A2 (en) 2005-10-11 2006-10-11 Nanobodies™ and polypeptides against egfr and igf-ir

Country Status (6)

Country Link
EP (1) EP1934259A2 (en)
JP (1) JP2009511032A (en)
CN (1) CN101321784A (en)
AU (1) AU2006301426A1 (en)
CA (1) CA2624781A1 (en)
WO (1) WO2007042289A2 (en)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2666599A1 (en) 2006-08-18 2008-02-21 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
US9512236B2 (en) 2006-12-19 2016-12-06 Ablynx N.V. Amino acid sequences directed against GPCRS and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
CA2588106A1 (en) * 2007-05-18 2008-11-18 Nrc - Institute For Biological Sciences Single-domain antibodies and heavy chain antibody against egfr and uses thereof
US20110282033A1 (en) * 2007-05-24 2011-11-17 Ablynx N.V. Amino acid sequences directed against growth factor receptors and polypeptides comprising the same for the treatment of diseases and disorders associated with growth factors and their receptors
RU2481355C2 (en) 2007-05-24 2013-05-10 Аблинкс Н.В. Rank-l targeted amino acid sequences and polypeptides containing them for treating bone diseases and disorders
WO2009068628A1 (en) * 2007-11-27 2009-06-04 Ablynx N.V. Constructs comprising single variable domains and an fc portion derived from lge.
WO2009127691A1 (en) 2008-04-17 2009-10-22 Ablynx N.V. Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
PL2274331T3 (en) 2008-05-02 2014-04-30 Novartis Ag Improved fibronectin-based binding molecules and uses thereof
AU2009248049B2 (en) 2008-05-16 2015-07-23 Ablynx N.V. Amino acid sequences directed against CXCR4 and other GPCRs and compounds comprising the same
US8444976B2 (en) 2008-07-02 2013-05-21 Argen-X B.V. Antigen binding polypeptides
EP2143735A1 (en) * 2008-07-10 2010-01-13 Institut Pasteur Variable domains of camelid heavy-chain antibodies directed against glial fibrillary acidic proteins
GB0814960D0 (en) * 2008-08-15 2008-09-24 Ge Healthcare As Method for detecting dysplasia
EP2370465B1 (en) 2008-12-19 2019-01-23 Ablynx N.V. Genetic immunization for producing immunoglobulins against cell-associated antigens such as p2x7, cxcr7 or cxcr4
US9265834B2 (en) 2009-03-05 2016-02-23 Ablynx N.V. Stable formulations of polypeptides and uses thereof
EP2403873A1 (en) * 2009-03-05 2012-01-11 Ablynx N.V. Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof
MA33198B1 (en) * 2009-03-20 2012-04-02 Genentech Inc ANTI-HER DI-SPECIFIC ANTIBODIES
WO2010112194A1 (en) * 2009-04-02 2010-10-07 F. Hoffmann-La Roche Ag Antigen-binding polypeptides and multispecific antibodies comprising them
CA2758191C (en) 2009-04-10 2015-06-30 Ablynx N.V. Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
EP2417162A2 (en) 2009-04-10 2012-02-15 Ablynx N.V. Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
WO2010146059A2 (en) 2009-06-16 2010-12-23 F. Hoffmann-La Roche Ag Biomarkers for igf-1r inhibitor therapy
PL2473528T3 (en) 2009-09-03 2015-05-29 Ablynx Nv Stable formulations of polypeptides and uses thereof
WO2011051333A1 (en) 2009-10-30 2011-05-05 Novartis Ag Universal fibronectin type iii bottom-side binding domain libraries
WO2011051327A2 (en) 2009-10-30 2011-05-05 Novartis Ag Small antibody-like single chain proteins
WO2011051466A1 (en) 2009-11-02 2011-05-05 Novartis Ag Anti-idiotypic fibronectin-based binding molecules and uses thereof
CN111500474B (en) * 2009-12-18 2023-10-03 诺维信股份有限公司 Methods for producing polypeptides in protease-deficient mutants of Trichoderma
WO2011083141A2 (en) 2010-01-08 2011-07-14 Ablynx Nv Method for generation of immunoglobulin sequences by using lipoprotein particles
JP2013518853A (en) 2010-02-05 2013-05-23 アブリンクス エン．ヴェー． Peptides capable of binding to serum albumin and compounds, constructs and polypeptides containing the same
WO2011117423A1 (en) 2010-03-26 2011-09-29 Ablynx N.V. Immunoglobulin single variable domains directed against cxcr7
NZ603570A (en) 2010-05-20 2014-12-24 Ablynx Nv Biological materials related to her3
GB201014715D0 (en) * 2010-09-06 2010-10-20 Vib Vzw Nanobodies stabilizing functional conformational states of GPCRS
EP2621953B1 (en) 2010-09-30 2017-04-05 Ablynx N.V. Biological materials related to c-met
CN102153650B (en) * 2011-01-27 2012-07-04 中国人民解放军军事医学科学院生物工程研究所 Anti-EGFR (epidemic growth factor receptor) humanized antibody L2-H3 and coding gene and application thereof
US20150158948A9 (en) 2011-03-28 2015-06-11 Francis Descamps Bispecific anti-cxcr7 immunoglobulin single variable domains
UA117218C2 (en) 2011-05-05 2018-07-10 Мерк Патент Гмбх POLYPEPTIDE AGAINST IL-17A, IL-17F AND / OR IL17-A / F
KR102072250B1 (en) 2011-05-27 2020-03-02 아블린쓰 엔.브이. Inhibition of bone resorption with rankl binding peptides
CN102321175B (en) * 2011-09-21 2013-08-07 天津胜发生物技术有限公司 Nano-antibody or polypeptide aiming at breast cancer Her2/new
AU2012311443B2 (en) 2011-09-23 2016-12-01 Ablynx Nv Prolonged inhibition of interleukin-6 mediated signaling
CN103889451B (en) 2011-09-30 2016-06-29 埃博灵克斯股份有限公司 Biological substances associated with C-Met
TWI641619B (en) * 2012-06-25 2018-11-21 美商再生元醫藥公司 anti-EGFR antibody and use thereof
KR20150037953A (en) 2012-07-13 2015-04-08 각코호진 데이쿄 헤이세이 다이가쿠 Anti-tumour agent, marker for tumour detection, and oral vaccine agent
AU2013372026B2 (en) 2013-01-03 2018-11-08 Merck Patent Gmbh Method for producing secretable antibodies by expression in saccharomyces cerevisiae
US20160251440A1 (en) * 2013-09-26 2016-09-01 Ablynx N.V. Bispecific nanobodies
JP6541237B2 (en) * 2014-03-06 2019-07-10 ナショナル リサーチ カウンシル オブ カナダ Insulin-like growth factor 1 receptor specific antibodies and their use
EA035517B1 (en) * 2014-03-06 2020-06-29 Нэшнл Рисеч Каунсил Оф Канада Insulin-like growth factor 1 receptor-specific antibodies and uses thereof
EA035472B1 (en) * 2014-03-06 2020-06-22 Нэшнл Рисеч Каунсил Оф Канада Insulin-like growth factor 1 receptor-specific antibodies and uses thereof
CA2943329A1 (en) 2014-03-24 2015-10-01 Genentech, Inc. Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
WO2016062766A1 (en) 2014-10-21 2016-04-28 Ablynx Nv Treatment of il-6r related diseases
KR101679245B1 (en) 2014-12-09 2016-11-25 전남대학교산학협력단 A composition for diagnosing or imaging cancer targeting epidermal growth factor receptor
ES2772348T3 (en) 2014-12-19 2020-07-07 Ablynx Nv Nanobody dimers with cysteine linkages
CN106854244B (en) * 2015-12-09 2020-05-22 南京英瀚斯生物科技有限公司 Nano antibody aiming at HER3 and clinical application thereof
US12128102B2 (en) 2016-03-08 2024-10-29 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins
IL313895A (en) * 2016-09-14 2024-08-01 Teneoone Inc Cd3 binding antibodies
CN106492216A (en) * 2016-10-28 2017-03-15 山西纳安生物科技有限公司 Nano antibody drug-delivery preparation system and preparation method and application through exocuticle in incidence
NZ754713A (en) 2016-12-21 2025-11-28 Teneobio Inc Anti-bcma heavy chain-only antibodies
US12049493B2 (en) 2017-01-06 2024-07-30 Abl Bio Inc. Anti-alpha-synuclein antibodies and uses thereof
WO2019016237A1 (en) * 2017-07-19 2019-01-24 Vib Vzw Serum albumin binding agents
CN109996872A (en) * 2017-07-20 2019-07-09 深圳普瑞金生物药业有限公司 A kind of EGFR single domain antibody CART and its application for treating tumour
IL302614B2 (en) * 2017-09-08 2025-04-01 Maverick Therapeutics Inc Constrained conditionally activated binding proteins
AU2018385230B2 (en) * 2017-12-14 2022-10-13 Abl Bio Inc. Bispecific antibody to a-syn/IGF1R and use thereof
GB201721802D0 (en) * 2017-12-22 2018-02-07 Almac Discovery Ltd Ror1-specific antigen binding molecules
US12037382B2 (en) * 2018-02-05 2024-07-16 Stichting Vu Inverse agonistic anti-US28 antibodies
CN112521504B (en) * 2018-09-27 2022-08-16 暨南大学 Anti-human EGFR nano antibody and application thereof
CN114390938B (en) 2019-03-05 2025-03-21 武田药品工业有限公司 constrained conditionally activated binding protein
WO2021006819A1 (en) * 2019-07-10 2021-01-14 Nanyang Technological University Epidermal growth factor receptor (egfr) ligands
CN111171151B (en) * 2019-12-26 2021-09-14 佛山汉腾生物科技有限公司 anti-EGFR (epidermal growth factor receptor) nano antibody and application thereof
US20230058519A1 (en) * 2019-12-28 2023-02-23 Shanghai Cell Therapy Group Company Co., Ltd. Cell Expressing Immune Modulatory Molecules and System for Expressing Immune Modulatory Molecules
CN112375135B (en) * 2020-07-06 2022-12-23 上海大学 Artificial epidermal growth factor, designed polypeptide and application thereof
WO2022109611A1 (en) 2020-11-20 2022-05-27 Simcere Innovation, Inc. Armed dual car-t compositions and methods for cancer immunotherapy
CN112646035B (en) * 2020-12-25 2022-06-24 暨南大学 Affinity maturation binding protein of EGFR (epidermal growth factor receptor) and application
CN112646034B (en) * 2020-12-25 2022-06-24 暨南大学 Affinity mature binding protein of EGFR and its application
IL309957A (en) 2021-07-14 2024-03-01 2Seventy Bio Inc Transgenic T cell receptors attached to antibody binding sites
CA3228014A1 (en) 2021-07-30 2023-02-16 Vib Vzm Cation-independent mannose-6-phosphate receptor binders for targeted protein degradation
KR20240099227A (en) * 2021-10-18 2024-06-28 타보텍 바이오테라퓨틱스 (홍콩) 리미티드 Anti-EGFR antibodies, anti-cMET antibodies, anti-VEGF antibodies, multispecific antibodies, and uses thereof
KR20240135670A (en) * 2022-01-29 2024-09-11 밍훼이 파마슈티컬 (항저우) 리미티드 Antigen binding proteins and uses thereof
CN117343194B (en) * 2022-02-09 2024-03-05 青岛大学附属医院 Trispecific nanobodies targeting PD-L1/HSA/CCL5 and their derivatives and applications
CN119546328A (en) 2022-04-08 2025-02-28 再生元制药公司 Multipartite receptor and signaling complexes
CN120265326A (en) * 2022-11-25 2025-07-04 明慧医药（杭州）有限公司 An antitumor compound and its application
AR131494A1 (en) 2022-12-23 2025-03-26 Ablynx Nv PROTEIN-BASED CONJUGATION VEHICLES
CN120712282A (en) 2023-02-17 2025-09-26 阿布林克斯有限公司 Polypeptides that bind neonatal FC receptors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030165502A1 (en) * 2000-06-13 2003-09-04 City Of Hope Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth
WO2005016970A2 (en) * 2003-05-01 2005-02-24 Imclone Systems Incorporated Fully human antibodies directed against the human insulin-like growth factor-1 receptor
WO2005044858A1 (en) * 2003-11-07 2005-05-19 Ablynx N.V. Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses therefor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030165502A1 (en) * 2000-06-13 2003-09-04 City Of Hope Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth
WO2005016970A2 (en) * 2003-05-01 2005-02-24 Imclone Systems Incorporated Fully human antibodies directed against the human insulin-like growth factor-1 receptor
WO2005044858A1 (en) * 2003-11-07 2005-05-19 Ablynx N.V. Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses therefor

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ELS CONRATH K ET AL: "Camel single-domain antibodies as modular building units in bispecific and bivalent antibody constructs", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 276, no. 10, 9 March 2001 (2001-03-09), pages 7346 - 7350, XP002248402, ISSN: 0021-9258 *
LU D ET AL: "Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 279, no. 4, 23 January 2004 (2004-01-23), pages 2856 - 2865, XP002316541, ISSN: 0021-9258 *
RUDIKOFF S ET AL: "Single amino acid substitution altering antigen-binding specificity", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 79, March 1982 (1982-03-01), pages 1979 - 1983, XP007901436, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
EP1934259A2 (en) 2008-06-25
WO2007042289A2 (en) 2007-04-19
JP2009511032A (en) 2009-03-19
AU2006301426A1 (en) 2007-04-19
CN101321784A (en) 2008-12-10
CA2624781A1 (en) 2007-04-19

Similar Documents

Publication Publication Date Title
WO2007042289A3 (en) Nanobodies™ and polypeptides against egfr and igf-ir
PH12012502272A1 (en) Biological materials related to her3
WO2009068627A3 (en) Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
WO2008077945A3 (en) Anti-chemokine (ccl2, ccl3, ccl5, cxcl11, cxcl12) single-domain antibodies
IL250946B (en) Nanobodies tm against tumor necrosis factor-alpha
WO2008066752A8 (en) Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir
WO2006122825A3 (en) Single domain vhh antibodies against von willebrand factor
WO2008142164A3 (en) Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders
WO2008074867A3 (en) Anti-fc-receptor single domain antibodies (nanobodies-tm) and therapeutic use
WO2010120514A3 (en) Antigen-binding proteins comprising recombinant protein scaffolds
WO2006119987A3 (en) Recombinant n-glycosylated proteins from procaryotic cells
WO2008074839A3 (en) Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders
WO2007104529A3 (en) Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
WO2008119566A3 (en) Cross-species-specific bispecific binders
WO2008025516A3 (en) Tnf superfamily fusion proteins
WO2008119565A3 (en) Cross-species-specific binding domain
WO2010051274A3 (en) Fibronectin type iii domain based scaffold compositions, methods and uses
WO2005121331A3 (en) Truncated galnact2 polypeptides and nucleic acids
WO2008005470A3 (en) Polypeptides that bind membrane proteins

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680044968.8

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006792421

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006301426

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2624781

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2008534933

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 12083406

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 3070/DELNP/2008

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2006301426

Country of ref document: AU

Date of ref document: 20061011

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006301426

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2006792421

Country of ref document: EP